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INTRODUCTION:  Soft  tissue  sarcomas  of  the  chest  wall  are  exceptionally  rare entities  that  present  as
painless  slow  growing  masses.  Resection  is  often  precarious  due  to  involvement  of vital  structures,  and
patients  are  left  with  large  chest  wall  defects  postoperatively  requiring  extensive  reconstruction.
PRESENTATION  OF  CASE:  We  present  a case  report  of a 29 year-old  man  who  presented  with  a  giant  soft
tissue  sarcoma  of the  chest  that  had  been  growing  slowly  for one  year  prior  to presentation.  The  patient
had  a biopsy  that  was  positive  for sarcoma,  and  PET  CT  demonstrated  a large  lobulated  mass  in the left
chest  wall  with  an  SUV  of  6.7.  He received  50 Gy of  radiation  therapy;  however,  the  mass  continued  to
grow  in  size.  He  subsequently  underwent  an en-bloc  resection  of the  mass  with  latissimus  and  serratus
muscle  primary  reconstruction.  Final  pathology  showed  a 27 cm high-grade  ﬁbrosarcoma  with  prominent
myxoid  component.  To  our knowledge,  this  is the  largest  soft  tissue  sarcoma  of  the  chest  wall  reported
in  the  literature.  Postoperatively,  the patient  received  6 cycles  of adjuvant  chemotherapy.
DISCUSSION:  Surgery  is  the  mainstay  of  treatment,  and chemotherapy  and  radiation  are  used  in  speciﬁc
circumstances.  Risk  of  recurrence  is dependent  on  many  factors,  including  histologic  subtype,  grade,  and
size of tumor.  Long  term  surveillance  with  physical  exam  and  imaging  is recommended.
CONCLUSION:  We  feel  that the multidisciplinary  approach  is  crucial  for  optimal  management  of large  soft
tissue  sarcomas.  We  recommend  this  approach  to all patients  with  chest  wall  sarcomas.
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. Introduction
Most soft tissue sarcomas (STS) of the chest wall present as pain-
ess slow growing masses [1–4] and approximately 0.1–0.15% of all
dult malignancy is chest wall STS [5]. Chest wall tumors have a
0% malignancy rate and comprise <5% of all thoracic malignan-
ies [6]. Chest wall tumors may  represent primary or metastatic
esions or may  be due to direct invasion of by an intrathoracic
ass [6]. These tumors pose a challenge to treating physicians, as
urgery is the mainstay of treatment; however, resection is often
recarious due to involvement of vital structures [2,6]. Addition-
lly, patients are left with large chest wall defects post operatively,
hich require extensive reconstruction [1,4,5,7]. We  report man-
gement of a giant STS of chest wall.. Case
A 29 year old male presented to our thoracic surgery clinic with
 left chest wall mass which he reported to be growing over the
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past year. The patient decided to seek medical treatment when
he developed a mild pain at the site of the mass one-week prior
to his presentation. On exam, the patient had a large chest wall
mass. A computed tomography (CT) scan of the chest showed a
17.5 cm × 11.5 cm large lobulated mass, and a positron emission
tomograph (PET)-CT showed uptake at the mass with an stan-
dardized uptake value (SUV) of 6.7 with no evidence of metastatic
disease. He underwent a biopsy that was positive for sarcoma.
The case was presented at the multidisciplinary thoracic tumor
board, and given the size of the mass, he was recommended to
undergo induction radiation therapy followed by surgery and sub-
sequent chemotherapy. The mass continued to grow in size despite
undergoing 50 Gy of radiation therapy. Patient then underwent
an en-bloc resection of the mass with a 2 cm margin (R0 resec-
tion) arising from the serratus muscle with partial resection of
lattisimus muscle. The ribs were not involved, and thus no chest
wall resection was  performed. A latissimus and serratus muscle
primary reconstruction was  performed by plastic surgery to cover
the large defect. Final pathology showed a 27 cm × 16 cm × 16 cm
high-grade (grade 3) ﬁbrosarcoma with prominent myxoid com-
ponent. To our knowledge, this is the largest STS of the chest wall
reported in the literature. Six weeks later, the patient received 6
cycles of ifosfamide and adriamycin. The patient had disease free
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Preoperative CT scan demonstrates large chest wall mass on (a) coronal and (b) axial views.
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sFig. 2. Large chest wall sarcoma measuring 27 cm × 16
urvival for 12 months, after which he developed metastatic dis-
ase in the lung and the pleura without evidence of local recurrence
Figs. 1 and 2).
. Discussion
The largest published review on STS by McMillan et al. com-
rised of 192 patients and found the most common histologic
ubtype to be desmoid tumor [3]. Five and ten-year survival rates
ere 73% and 61%, respectively, with a median survival of 14 years.
wenty-three percent of patients presented with recurrence of
isease at a median of 11.6 months for local recurrence versus
3.5 months for distant recurrence. According to the study, tumors
5 cm and high-grade tumors had the highest risk for recurrence,
nd the histologic subtype associated with the greatest recurrence
ate was an undifferentiated pleomorphic sarcoma. Five and ten-
ear survival rates after recurrence were 30% and 18%, respectively,
ith a median survival of 19.4 months.
CT scan of the chest is usually the ﬁrst diagnostic test for work
p of a chest wall mass. Since the lungs are the most common site of
etastasis, they are included in the initial survey [4,7,8]. MRI  of the
hest may  also be performed to assess any anatomic challenges in
lanning for resection, such as proximity of adjacent neurovascular
tructures [4,7–9]. PET-CT may  also be used in certain instances, 16 cm demonstrated (a) during and (b) after excision.
especially more high-risk patients, such as those with large, high-
grade tumors, for metastatic work up [10].
Prior to deﬁnitive treatment, biopsy is performed to deter-
mine treatment planning. While lesions <5 cm that are amenable
to resection may  undergo excisional biopsy, lesions >5 cm or in
anatomically challenging locations should typically undergo Tru-
cut needle biopsy or incisional biopsy for tissue diagnosis [6].
Surgical resection is the treatment of choice for STS of the chest
wall [2,3,5,9]. R0 resection can be obtained in up to 80% of patients
and is critical for risk reduction of disease recurrence [5]. Neoad-
juvant/adjuvant therapies are used in speciﬁc cases: radiation is
used in patients with positive margins or high risk of recurrence [8];
however, radiation has not been shown to improve disease-speciﬁc
survival [4,5]. Neoadjuvant radiation may  be used in patients with
large, high-grade tumors if wound complications are not antici-
pated and it is advantageous to adjuvant radiotherapy with lower
rates of late morbidity including ﬁbrosis and bone fracture [11]. In
our patient, radiation therapy had very little impact on the size of
the tumor. Chemotherapy is used sparingly as most sarcomas are
minimally responsive, but it may  be considered for large (> 5 cm)
and high grade STS [11].Finally, many patients require complicated chest wall recon-
struction after resection of their sarcoma, especially when multiple
ribs have to be resected [6,7]. Surgeries are most often success-
ful with a multidisciplinary approach including plastic surgery.
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arge defects necessitate mesh and/or musculocutaneous ﬂaps for
hest wall stabilization and avoidance of paradoxical respiratory
ovements [7,9]. Most commonly, a latissimus dorsi ﬂap is used,
owever, bilateral pectoral ﬂaps are also useful, especially in the
ase of sternal resection [1].
Patients must have routine follow-up with physical examination
nd be counseled on self-examination for detection of recurrence
3]. Additionally, patients should undergo CT screening for surveil-
ance of their tumor [3].
. Conclusion
This case represents an example of the complexity of treating
atient with giant STS. We  feel that a multidisciplinary approach
ncluding thoracic surgery, plastic surgery, medical oncology, and
adiation oncology is crucial to optimal management of this difﬁcult
isease process. We recommend this approach to all patients with
hest wall sarcomas.
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